Hepatitis c virus infection Trials in Vancouver, Canada
Conditions / Hepatitis c virus infection / Vancouver, Canada
Clinical trials for Hepatitis c virus infection investigate a range of treatment strategies and patient populations.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02114151 | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis | COMPLETED | PHASE3 |
| NCT02201953 | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection | COMPLETED | PHASE3 |
| NCT01428063 | Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials | COMPLETED | PHASE2 |
| NCT02639338 | Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | COMPLETED | PHASE3 |
| NCT02600351 | Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies | TERMINATED | PHASE3 |
| NCT02346721 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection | COMPLETED | PHASE3 |
| NCT02201940 | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection | COMPLETED | PHASE3 |
| NCT02292706 | A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection | TERMINATED | — |
| NCT02114177 | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis | COMPLETED | PHASE3 |
| NCT02639247 | Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor | COMPLETED | PHASE3 |